Cardiol Therapeutics Inc.

NasdaqCM:CRDL Stock Report

Market Cap: US$124.8m

Cardiol Therapeutics Management

Management criteria checks 2/4

Cardiol Therapeutics' CEO is David Elsley, appointed in Jan 2017, has a tenure of 7.83 years. total yearly compensation is CA$748.10K, comprised of 70.2% salary and 29.8% bonuses, including company stock and options. directly owns 1.51% of the company’s shares, worth $1.88M. The average tenure of the management team and the board of directors is 3.9 years and 2.8 years respectively.

Key information

David Elsley

Chief executive officer

CA$748.1k

Total compensation

CEO salary percentage70.2%
CEO tenure7.8yrs
CEO ownership1.5%
Management average tenure3.9yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Elsley's remuneration changed compared to Cardiol Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$36m

Jun 30 2024n/an/a

-CA$29m

Mar 31 2024n/an/a

-CA$30m

Dec 31 2023CA$748kCA$525k

-CA$28m

Sep 30 2023n/an/a

-CA$28m

Jun 30 2023n/an/a

-CA$30m

Mar 31 2023n/an/a

-CA$29m

Dec 31 2022CA$654kCA$525k

-CA$31m

Sep 30 2022n/an/a

-CA$30m

Jun 30 2022n/an/a

-CA$32m

Mar 31 2022n/an/a

-CA$32m

Dec 31 2021CA$1mCA$455k

-CA$32m

Sep 30 2021n/an/a

-CA$35m

Jun 30 2021n/an/a

-CA$30m

Mar 31 2021n/an/a

-CA$27m

Dec 31 2020CA$517kCA$450k

-CA$21m

Sep 30 2020n/an/a

-CA$14m

Jun 30 2020n/an/a

-CA$13m

Mar 31 2020n/an/a

-CA$13m

Dec 31 2019CA$450kCA$450k

-CA$14m

Sep 30 2019n/an/a

-CA$20m

Jun 30 2019n/an/a

-CA$21m

Mar 31 2019n/an/a

-CA$19m

Dec 31 2018CA$713kCA$363k

-CA$16m

Compensation vs Market: David's total compensation ($USD535.83K) is about average for companies of similar size in the US market ($USD653.78K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Elsley

7.8yrs

Tenure

CA$748,100

Compensation

Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...

Leadership Team

NamePositionTenureCompensationOwnership
David Elsley
President7.8yrsCA$748.10k1.51%
$ 1.9m
Christopher Waddick
CFO, Corporate Secretary & Director6.3yrsCA$294.80k0.14%
$ 171.8k
Bernard Lim
Chief Operating Officer3.9yrsCA$515.90k0.038%
$ 46.8k
Andrew Hamer
Chief Medical Officer & Head of Research & Development3.7yrsCA$746.56k0.56%
$ 699.1k
Trevor Burns
Investor Relationsno datano datano data
John Geddes
Vice President of Corporate Developmentless than a yearno datano data

3.9yrs

Average Tenure

Experienced Management: CRDL's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Elsley
President7.8yrsCA$748.10k1.51%
$ 1.9m
Christopher Waddick
CFO, Corporate Secretary & Director2.5yrsCA$294.80k0.14%
$ 171.8k
Colin Stott
Independent Director4.9yrsCA$60.00k0.18%
$ 222.5k
Jennifer Chao
Independent Director2.7yrsCA$76.92k0.13%
$ 156.1k
Peter Pekos
Independent Director6.9yrsCA$58.00k0.58%
$ 729.6k
Michael Willner
Independent Director3.2yrsCA$71.52k1.07%
$ 1.3m
Paul Ridker
Member of Scientific Advisory Board2.8yrsno datano data
Bruce McManus
Member of Scientific Advisory Board2.8yrsno datano data
Teri Loxam
Independent Director2.5yrsCA$82.32k0.15%
$ 187.4k
Guillermo Torre-Amione
Independent Chairman6.3yrsCA$112.68k0.28%
$ 344.3k
Joseph Hill
Member of Scientific Advisory Board2.8yrsno datano data

2.8yrs

Average Tenure

56yo

Average Age

Experienced Board: CRDL's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.